CYTOMX THERAPEUTICS INC. - COMMON STOCK

CytomX Therapeutics to Present at Upcoming March Investor Conferences

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

24 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

12 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

21 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

07 Nov 2023 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

18 Oct 2023 15:30:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming September Investor Conferences

05 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

10 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

08 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

01 Aug 2023 07:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

20 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

17 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

30 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

01 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

09 May 2023 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

01 May 2023 15:01:00 By Nasdaq GlobeNewswire